psoriasis vulgaris in the 1980s and was initially treated topically with steroids, dithranol and phototherapy, followed by systemic therapy with fumarate, cyclosporine, and methotrexate. Owing to signs of psoriasis arthritis, anti-TNF-α treatment with adalimumab was initiated in September 2015, leading to almost complete remission of the psoriasis.
However, in early 2017, about 18 months after treatment initiation, the patient first perceived hypesthesia of the lower limbs [corresponding to an Expanded Disability Status Scale (EDSS) score of 2.0], which progressed slowly over the following months. Adalimumab treatment was therefore discontinued in April 2017. Over the course of approximately 1 year, slowly progressive gait impairment, strangury, visual impairment and dysarthria occurred subsequently. Neurological examination in November 2018 revealed gait impairment owing to spasticity and ataxia with a restricted walking distance of about 2 km, severe pallhypaesthesia and brain stem symptoms including saccadic eye movement and dysarthria (corresponding to an EDSS score of 4.0). Visually evoked potentials (VEPs) displayed prolonged latencies of both optic nerves. Magnetic resonance imaging (MRI) of the brain and spinal cord showed numerous T2-hyperintensive lesions without contrast enhancement in periventricular, juxtacortical and spinal localization ( Figure 1A -D). Cerebrospinal fluid (CSF) analysis revealed a slight pleocytosis, intrathecal immunoglobulin synthesis, and presence of CSF-specific oligoclonal bands. Tests for serum antibodies against Aquaporin-4 and MOG were negative. Infectious or other autoimmunological causes were ruled out.
As the patient fulfilled all diagnostic criteria according to the 2017 revision of the McDonald criteria (progressive neurological symptoms >12 months, MRI lesions typical for MS, positive CSF and pathologic VEPs), 1 PPMS was diagnosed. Disease-modifying treatment with ocrelizumab was initiated and complemented by topical steroids for treating psoriatic symptoms.
The patient had no family history of multiple sclerosis or other neurological diseases. He gave written informed consent for both performing genomic sequencing and publishing its results, along with clinical data, radiological findings and results of laboratory tests in this case report.
Review of reported cases
As anti-TNF-α therapy-associated demyelinating disorders, including monophasic demyelinating events and peripheral demyelinating syndromes, have already been reviewed extensively in the past, 2-6 we focused on those reports describing a definite diagnosis of MS (Table 1) .
We identified 20 cases of MS onset upon anti-TNF-α therapies, of which 9 were diagnosed with RRMS according to the McDonald criteria. [23] [24] [25] In 8 further cases, MS disease course was described as RRMS, but diagnostic criteria were not specified. One case could not be classified owing to a paucity of clinical data. There was one case description of slowly progressing neurological deficits, in which the available clinical information allowed no differentiation between secondary and primary progressive disease course, 21 and one report about the exacerbation of preexisting PPMS in a patient treated with etanercept. 22 Four patients had a positive family history for MS. 8, 13, 17, 21 Discussion MS is a heterogeneous disease, which may be categorized into clinically isolated syndrome (CIS), RRMS, secondary progressive MS (SPMS) and PPMS. Lately, there have been suggestions to also include radiologically isolated syndrome (RIS), which is defined by MRI lesions suggestive for MS without clinical manifestation, as a prodrome of MS diseases since around one-third of patients with asymptomatic lesions develops neurological symptoms later on. 26 Interestingly, some RIS patients progress directly to PPMS. 27 This supports the hypothesis that all MS subtypes share some biological aspects in their pathogenesis, although it is still unknown why some patients suffer from acute relapses, whereas others progress relapse independently.
Although the possibility that the patient reported here had preexisting MS that was unmasked by adalimumab treatment, or that PPMS onset occurred coincidentally with adalimumab therapy cannot be fully excluded, our case suggests a crucial role of deregulated TNF-α homeostasis in the evolution of all MS subtypes as it offers the first description of definite PPMS onset upon anti-TNF-α therapy and thereby extends the spectrum of demyelinating diseases associated with these drugs. The effects mediated by TNF-α are extremely complex, not least because they can be either proor anti-inflammatory depending on cell typespecific interpretation of TNF-triggered pathways. There are also two biologically active variants of TNF-α, a soluble and a transmembrane form, as well as two different receptors. TNF-α-receptor 1 (TNFR1)-activation is mainly associated with proinflammatory and cytotoxic signalling, whereas TNF-α-receptor 2 (TNFR2)-activation evokes cytoprotective pathways. 28 In MS, TNF-α levels were found to be increased in active MS lesions 29 and in an animal model of MS, TNFR1-deficiency led to amelioration of the disease course. 30 TNFR2-deficiency on the other hand resulted in enhanced susceptibility. 31 It is assumed that the activation of TNFR2 inhibits the pro-inflammatory activity of microglia, promotes the suppressive activity of regulatory T cells, enhances the differentiation of oligodendrocytes and stimulates remyelination. 28 It is therefore believed that in MS, in contrast to other autoimmune diseases, an imbalance in favour of pro-inflammatory TNFR1-mediated signalling pathways outweighs beneficial TNFR2-mediated effects. 32 Furthermore, genome-wide association studies have identified a link between the development of MS and the presence of the single nucleotide polymorphism (SNP) rs1800693 in the TNFRSF1A gene, which encodes TNFR1. 33 Presence of this SNP directs the expression of a novel, soluble form of TNFR1 that can block TNF-α, thus mimicking the effects of anti-TNF-α therapies. Carriers of this SNP might therefore be genetically prone to development or exacerbation of a demyelinating disease upon anti-TNF-α treatment. 34 Supporting this hypothesis, our patient was also found to carry the rs1800693 SNP ( Figure 1E ). Interestingly, no such association has been described for other autoimmune conditions such as rheumatoid arthritis, psoriasis or Crohn's disease, in which anti-TNF-α treatment has a beneficial effect. 34 In the future, genetic testing might be of use to stratify patients according to their individual propensity for developing demyelinating disease upon anti-TNF-α therapy.
We believe that this case of PPMS onset upon adalimumab treatment is of clinical importance as it extends the spectrum of demyelinating disorders associated with anti-TNF-α therapy. In PPMS, neurological deficits are often very subtle in the beginning and usually progress slowly, which may impede diagnosis. However, as early treatment discontinuation is thought to improve the patient's outcome, it is important to increase the awareness of slowly progressing neurological symptoms as a potential adverse event among all clinicians involved in the initiation and monitoring of anti-TNF-α therapies. In addition, our case supports the hypothesis of a shared pathophysiological mechanism involving dysregulation of TNF-α homeostasis in the evolution of both relapsing and progressing MS.
